

# CNF1 (NG8): sc-52655

## BACKGROUND

Cytotoxic necrotizing factor 1 (CNF1) is a toxin produced by uropathogenic and meningitis-causing *Escherichia coli*. CNF1 catalyzes the permanent activation of Rho-GTP-binding proteins (Rho, Rac and Cdc42) by deamidation or trans-glutamination, which induces a reorganization of the Actin cytoskeleton into large stress fibers as well as the multiplication of focal contact points. The toxin binds to cells and is subsequently internalized by endocytosis and transported into late endosomes. The middle toxin domain has two hydrophobic helices that enable the toxin to be translocated across the membrane upon acidification in late endosomes. CNF1 may play a role in interfering with the occurrence of mitotic catastrophe (mammalian cell death caused by aberrant mitosis) and leads to aneuploidy and multinucleation.

## REFERENCES

1. Schmidt, G., Sehr, P., Wilm, M., Selzer, J., Mann, M. and Aktories, K. 1997. Gln 63 of Rho is deamidated by *Escherichia coli* cytotoxic necrotizing factor-1. *Nature* 387: 725-729.
2. Boquet, P. 1998. Cytotoxic necrotizing factor 1 from *Escherichia coli*: a toxin with a new intracellular activity for eukaryotic cells. *Folia Microbiol.* 43: 285-289.
3. Vouret-Craviari, V., Grall, D., Flatau, G., Pouyssegur, J., Boquet, P. and Van Obberghen-Schilling, E. 1999. Effects of cytotoxic necrotizing factor 1 and VE-cadherin localization in human endothelial cell monolayers. *Infect. Immun.* 67: 3002-3008.
4. Boquet, P. 2001. The cytotoxic necrotizing factor 1 (CNF1) from *Escherichia coli*. *Toxicon* 39: 1673-1680.
5. Meysick, K., Mills, M. and O'Brien, A.D. 2001. Epitope mapping of monoclonal antibodies capable of neutralizing cytotoxic necrotizing factor type 1 of uropathogenic *Escherichia coli*. *Infect. Immun.* 69: 2066.
6. Landraud, L., Pulcini, C., Gounon, P., Flatau, G., Boquet, P. and Lemichez, E. 2004. *E. coli* CNF1 toxin: a two-in-one system for host-cell invasion. *Int. J. Med. Microbiol.* 293: 513-518.
7. Boyer, L., Turchi, L., Desnues, B., Doye, A., Ponzio, G., Mege, J.L., Yamashita, M., Zhang, Y.E., Bertoglio, J., Flatau, G., Boquet, P. and Lemichez, E. 2006. CNF1-induced ubiquitylation and proteasome destruction of activated RhoA is impaired in Smurf1<sup>-/-</sup> cells. *Mol. Biol. Cell* 17: 2489-2497.
8. Doye, A., Boyer, L., Mettouche, A. and Lemichez, E. 2006. Ubiquitin-mediated proteasomal degradation of Rho proteins by the CNF1 toxin. *Meth. Enzymol.* 406: 447-456.
9. Malorni, W. and Fiorentini, C. 2006. Is the Rac GTPase-activating toxin CNF1 a smart hijacker of host cell fate? *FASEB J.* 20: 606-609.

## SOURCE

CNF1 (NG8) is a mouse monoclonal antibody raised against amino acids 704-730 at the C-terminal enzymatic domain of CNF1 of *E. coli* origin.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PRODUCT

Each vial contains 100 µg IgG<sub>2a</sub> in 1.0 ml of PBS with <0.1% sodium azide and 0.1% gelatin.

## APPLICATIONS

CNF1 (NG8) is recommended for detection of CNF1 of *E. coli* origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000).

Molecular Weight of CNF1: 115 kDa.

## SELECT PRODUCT CITATIONS

1. Knust, Z., Blumenthal, B., Aktories, K. and Schmidt, G. 2009. Cleavage of *Escherichia coli* cytotoxic necrotizing factor 1 is required for full biologic activity. *Infect. Immun.* 77: 1835-1841.
2. Guo, Y., Zhang, Z., Wei, H., Wang, J., Lv, J., Zhang, K., Keller, E.T., Yao, Z. and Wang, Q. 2017. Cytotoxic necrotizing factor 1 promotes prostate cancer progression through activating the Cdc42-PAK1 axis. *J. Pathol.* 243: 208-219.
3. Yang, H., Li, Q., Wang, C., Wang, J., Lv, J., Wang, L., Zhang, Z.S., Yao, Z. and Wang, Q. 2018. Cytotoxic necrotizing factor 1 downregulates CD36 transcription in macrophages to induce inflammation during acute urinary tract infections. *Front. Immunol.* 9: 1987.
4. Colarusso, A., Maroccia, Z., Parrilli, E., Germinario, E.A.P., Fortuna, A., Loizzo, S., Ricceri, L., Tutino, M.L., Fiorentini, C. and Fabbri, A. 2020. CNF1 variants endowed with the ability to cross the blood-brain barrier: a new potential therapeutic strategy for glioblastoma. *Toxins* 12: 291.
5. Tsoumtsa Meda, L.L., Landraud, L., Petracchini, S., Descamps-Declere, S., Perthame, E., Nahori, M.A., Ramirez Finn, L., Ingersoll, M.A., Patiño-Navarrete, R., Glaser, P., Bonnet, R., Dussurget, O., et al. 2022. The cnf1 gene is associated with an expanding *Escherichia coli* ST131 H30Rx/C2 subclade and confers a competitive advantage for gut colonization. *Gut Microbes* 14: 2121577.

## STORAGE

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.